Late-outcomes of TB-IRIS William Worodria, MBChB, MMed, PhD Senior EDCTP Fellow Infectious Disease Institute, Kampala, Uganda Mulago Hospital & Complex,

Slides:

Advertisements

Similar presentations

Tuberculosis incidence and risk factors among adult patients receiving HAART in Senegal: a 7-year cohort study Assane DIOUF et al. IRD/UMR 145 CRCF, CHNU.

Advertisements

Incidence and risks factors of paradoxical tuberculosis-associated IRIS in HIV-infected adults enrolled in the CAMELIA clinical trial ANRS 1295/CIPRA KH001.

The effect of changes in Kenya HIV guidelines on proportion of patients on ART and patient characteristics at initiation in Lumumba Health Centre, Western.

Risk factors and true outcomes of children lost to follow-up from antiretroviral therapy in Lilongwe, Malawi C. Ardura Gracia, H. Tweya, C Feldacker, S.

High Rates of Tuberculosis in Patients Accessing HAART in Rural South Africa – Implications for HIV and TB Treatment Programs Kogieleum Naidoo on behalf.

Recommendations of BU/HIV expert panel influenced by results from Akonolinga All BU patients should be offered quality provider-initiated HIV testing and.

Antiretroviral therapy eligibility at enrollment and time to treatment initiation in Ethiopia Chloe A. Teasdale 1, Chunhui Wang 1, Sileshi Lulseged 1,

Graeme Meintjes Department of Medicine, University of Cape Town HIV Service, GF Jooste Hospital TB-IRIS Research priorities and update from Kampala workshop.

Most deaths among children enrolled in two program settings in Cambodia occur within the first 6 months after enrolment. Early mortality rates were more.

Primary Healthcare Facilities Deliver More Effective Antiretroviral Therapy: An Evaluation in Four Provinces in South Africa Geoffrey Fatti, Ashraf Grimwood.

Decentralization of HIV care and treatment services in Central Province, Kenya: Adult patient characteristics and outcomes Presenting author: William Reidy,

Characteristics and Outcomes of a Population of Tuberculosis Inpatients in Lilongwe, Malawi Mina Hosseinipour, MD, MPH Clinical Director UNC Project Lilongwe,

Matthew Fox Center for Global Health & Development Department of Epidemiology Boston University July 17, 2011 The first step is admitting you have a problem.

Uptake of antiretrovirals in a cohort of women involved in high risk sexual behaviour in Kampala, Uganda J.Bukenya, M. Kwikiriza, O. Musana, J. Ssensamba,

1 Is Managed Care Superior to Traditional Fee-For-Service among HIV-Infected Beneficiaries of Medicaid? David Zingmond, MD, PhD UCLA Division of General.

Results of the CARINEMO ANRS randomized trial comparing the efficacy and safety of nevirapine vs efavirenz for treatment of HIV-TB co-infected patients.

Attrition in HIV Care Attrition in HIV Care: Key Operational Challenge in implementing HIV Care and Treatment in Tanzania G R Somi _________ Ministry of.

COST-BENEFIT OF INTEGRATING CRYPTOCOCCAL ANTIGEN SCREENING AND PREEMPTIVE TREATMENT INTO ROUTINE HIV CARE Radha Rajasingham, David Meya, Melissa Rolfes,

The impact of a limited subsidy on access to antiretroviral therapy (ART) and patient outcomes in Singapore Barnaby Young Infectious Diseases registrar.

HIV and AIDS Data Hub for Asia-Pacific Review in slides Treatment Last updated: December 2014.

Ukrainian TB mortality assessment 2008: Low HIV awareness and access to ART for TB patients associated with high HIV related TB mortality Presenting author:

The Timing of ART initiation in TB HIV co-infected patients: Impact on IRIS severity 6th IAS Conference on HIV Pathogenesis, Treatment and Prevention 20.

Edward Mills PhD, Associate Professor, Faculty of Health Sciences University of Ottawa AIDS Mortality Among Men in Africa: An overview of the evidence.

Press Briefing: Office of the Vice Chancellor MUK 6 th September 2010 The Infectious Diseases Institute Care and Research Initiatives Dr Alex G Coutinho.

Factors Associated with Survival in HIV-Infected African Patients on Antiretroviral Therapy: The Impact of a Sampling-Based Approach to Address Losses.

Good Three-year Outcomes of Antiretroviral Therapy at Multiple NGO- assisted facilities in Four Provinces in South Africa Geoffrey Fatti, Ashraf Grimwood.

Failure to Initiate ART, Loss to Follow-up and Mortality among HIV-infected Patients during the pre-ART period in Uganda Elvin H. Geng 1, Winnie Muyindike.

Integration of HIV and TB services results in earlier and more prioritised ART initiation in Uganda. Sabine Hermans 1,2,3, Barbara Castelnuovo 1, Andrew.

Data from the Collaborative HIV Paediatric Study (CHIPS) Reports up to March 2006* *Numbers are based on reports received rather than children seen to.

Efficacy of routine viral load, CD4 cell count, and clinical monitoring of adults taking antiretroviral therapy in Rural Uganda Alex Coutinho MD MPH DTM&H.

Switch to LPV/r monotherapy  Pilot LPV/r  M  LPV/r Mono  KalMo  OK  OK04  KALESOLO  MOST  HIV-NAT 077.

Q1 Which of the following descriptions about HIV and TB interaction is right ? Which of the following descriptions about HIV and TB interaction is right.

Outcomes of Antiretroviral Treatment Programs in Rural Lesotho: Health Centers and Hospitals Compared Niklaus Labhardt, Motlalepula Sello, Mamokone A.

Integration of TB and HIV Screening, Care and Treatment in Mulago Hospital, Uganda Rhoda Wanyenze, Doris Mwesigire, Henry Luzze, Violet Gwokyalya, Julius.

H Bygrave L Triviño L Makakole Medecins sans Frontieres Lesotho Scott Hospital Morija TB/HIV Integration Lessons learned from implementation of a TB/HIV.

Predictors of ART-associated TB in a prospective study: Results of the Kericho IRIS Study The Rainbow of IRIS in HIV Infection July 26, 2012 Fredrick.

Strategies for Management of Antiretroviral Therapy Study Wafaa El-Sadr and James Neaton for the SMART Study Team.

OUTCOME OF STAVUDINE INDUCED PERIPHERAL NEUROPATHY IN HIV-1 POSITIVE PATIENTS SWITCHED OR SUBSTITUTED TO A NON-STAVUDINE- BASED REGIMEN Dr P Gorejena-Chidawanyika.

Response to Antiretroviral Treatment In an Ethiopian Hospital Samuel Hailemariam, MD, MPH; J Allen McCutchan, MD, MSc Meaza Demissie, MD, PMH, PHD; Alemayehu.

HAART Initiation Within 2 Weeks of Seroconversion Associated With Virologic and Immunologic Benefits Slideset on: Hecht FM, Wang L, Collier A, et al. A.

CD4 trajectory among HIV positive patients receiving HAART in a large East African HIV care centre Agnes N. Kiragga 1, Beverly Musick 2 Ronald Bosch, Ann.

Initiation of Antiretroviral Therapy in Early Asymptomatic HIV Infection The INSIGHT START Study Group Ben Andres Oct 15, 2015.

Successfully enrolled in HIV Care but not linked to timely Treatment: Poor retention and Monitoring of Pre-ART patients who are not yet eligible for ART.

The Dynamics of HIV RNA, CD4+ Count and Mycobacterium tuberculosis (Mtb) Antigen Specific Cytokines in TB/HIV Patients Following Successful Tuberculosis.

1 Predictors of Immunological Failure Among Adult Patients Receiving ART at an urban, HIV Clinic in Uganda Dr. Muhumuza Simon (M.D, MPH) Mulago-Mbarara.

Randomized clinical trial to determine efficacy and safety of antiretroviral therapy one week after tuberculosis therapy in patients with CD4 counts

#AIDS2016 Intensified TB case-finding among PLHIV: diagnostic yield of Xpert MTB/RIF, Determine TB-LAM and liquid culture Fred Semitala,

1 NAME: TITLE:DATE:. 2 “One stop shop” for TB and HIV services improved initiation of antiretroviral therapy (ART) for co-infected patients in Eastern.

Adefovir Suppresses HBV DNA Levels in Lamivudine-Resistant HIV/HBV Patients Slideset on: Benhamou Y, Thibault V, Vig P, et al. Safety and efficacy of adefovir.

Factors associated with loss to follow up in a primary healthcare clinic practicing test and treat Authors: Julius Kiwanuka1,2, Noah Kiwanuka3, Flavia.

Sashindran V K, Sashwat S, Kumar Suman,

ART was initiated when indicated by WHO and national guidelines

I have no conflicts of interest to declare

The Ethiopian TB HAART study: Find out the timing for ART when CD4< 200cells/µL Anything new? Wondwossen Amogne, Abiy H/ wold, Getent Yimer,

coinciding with biphasic immune reconstitution

International Journal of Infectious Diseases

Daniel Meressa, M.D. Global Health Committee St. Peter’s Hospital

Table 1 Characteristics of study patients in survey of HIV infection in India. From: Natural History of Human Immunodeficiency Virus Disease in Southern.

Predictors of antiretroviral treatment associated tuberculosis in Ethiopia: a nested case control study Nebiyu Mesfin, MD.

Intensification with INSTI

Table 2. Mean intrasubject diversity for the 11 study participants, by genomic region. From: Hepatitis C Virus (HCV) Diversity in HIV-HCV-Coinfected Subjects.

Juan Gonzalez Perez AIDS Healthcare Foundation

Dorina Onoya1, Tembeka Sineke1, Alana Brennan1,2, Matt Fox1,2

Simeprevir in HIV Coinfection, GT-1 C212 Trial

24 July 2018 Treatment outcomes with bedaquiline use when substituted for second-line injectables in multidrug resistant tuberculosis: a retrospective.

Surveillance for TB in HIV Care and Treatment Settings (CTS)

Intensification with INSTI

Khai Hoan Tram, Jane O’Halloran, Rachel Presti, Jeffrey Atkinson

Public Health Implications

The IAS TB/HIV Research Prizes are awarded to:

Presentation transcript:

Late-outcomes of TB-IRIS William Worodria, MBChB, MMed, PhD Senior EDCTP Fellow Infectious Disease Institute, Kampala, Uganda Mulago Hospital & Complex, Kampala, Uganda The Rainbow of IRIS in HIV, 26th July 2012

Study objective To determine if there are differences in treatment outcomes between TB-HIV co-infected patients with and without TB-IRIS: CD4 changes with treatment Mortality Loss to follow up The Rainbow of IRIS in HIV, 26th July 2012

Methodology Site: Mulago National TB treatment centre Design: Case-control design. Inclusion criteria: – ART naïve adult patients co-infected with TB-HIV started on HAART (CD4<250) Exclusion criteria: – No treatment supporter – Severe liver/renal abnormalities Cases: patients with TB-IRIS Controls: patients without TB-IRIS -matched by baseline CD4 count (1:2) The Rainbow of IRIS in HIV, 26th July 2012

Results From December July 2010, we enrolled 254 patients with TB-HIV starting ART We identified: – 61 cases of TB-IRIS and – 122 controls (no TB-IRIS) The Rainbow of IRIS in HIV, 26th July 2012

The Rainbow of IRIS in HIV, 26th July 2012 Median CD4 counts of patients co-infected with TB-HIV on antiretroviral therapy

Treatment outcomes Mortality: 6 (10%) patients with TB-IRIS died vs 18 (15%) without TB-IRIS OR mortality = 0.60, 95% CI , (p= 0.34) Loss to Follow up: 5 (8.2%) patients with TB-IRIS vs 10 (8.2%) without were lost to follow up OR loss2fu = 1.00, 95% CI , (p=1.00) The Rainbow of IRIS in HIV, 26th July 2012

Conclusion TB-IRIS in this study with a small sample size had no impact on outcomes The Rainbow of IRIS in HIV, 26th July 2012

Acknowledgments The Rainbow of IRIS in HIV, 26th July 2012 Prof. R Colebunders Joseph Sempa All patients M-MJAP